Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4713610 | 0.98 | POLB (0.60) | POLBCHRNB2CHRNA4MEN1KMT2A | |
| SCHEMBL5790489 | 0.89 | POLB (0.69) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL24636855 | 0.86 | POLB (0.66) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL1570471 | 0.85 | CHRNB2 (0.46) | POLBCHRNB2CHRNA4MEN1KMT2A | |
| SCHEMBL19750331 | 0.84 | MEN1 (0.64) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL5889435 | 0.84 | MEN1 (0.69) | POLBMEN1KMT2AHTTKDM4E | |
| SCHEMBL1571019 | 0.84 | POLB (0.48) | POLBCHRNB2CHRNA4MEN1KMT2A | |
| SCHEMBL13450089 | 0.83 | POLB (0.63) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL3154235 | 0.83 | POLB (0.63) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL8791707 | 0.82 | MEN1 (0.61) | POLBMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| WO-2009098282-A1 | LOW MOLECULAR WEIGHT 2,5-DISUBSTITUTED THIOPHENE DERIVATIVES AND USE THEREOF IN THERAPY | NOVASAID AB (SE) | 2009-08-13 | — | — | WO | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
| CN-1280269-C | Aliphatic nitrogenous five-membered ring compound | TANABE SEIYAKU CO (JP) | 2006-10-18 | — | — | CN | disclosed |
| US-4243666-A | HYPOTENSIVE AGENTS | PFIZER INC. (US) | 1981-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | POLB 4709/4885CHRNB2 74/4885CHRNA4 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.